Cytosolic aldose metabolism contributes to progression from cirrhosis to hepatocarcinogenesis

Nat Metab. 2023 Jan;5(1):41-60. doi: 10.1038/s42255-022-00711-9. Epub 2023 Jan 19.

Abstract

Oxidative stress modulates carcinogenesis in the liver; however, direct evidence for metabolic control of oxidative stress during pathogenesis, particularly, of progression from cirrhosis to hepatocellular carcinoma (HCC), has been lacking. Deficiency of transaldolase (TAL), a rate-limiting enzyme of the non-oxidative branch of the pentose phosphate pathway (PPP), restricts growth and predisposes to cirrhosis and HCC in mice and humans. Here, we show that mitochondrial oxidative stress and progression from cirrhosis to HCC and acetaminophen-induced liver necrosis are critically dependent on NADPH depletion and polyol buildup by aldose reductase (AR), while this enzyme protects from carbon trapping in the PPP and growth restriction in TAL deficiency. Both TAL and AR are confined to the cytosol; however, their inactivation distorts mitochondrial redox homeostasis in opposite directions. The results suggest that AR acts as a rheostat of carbon recycling and NADPH output of the PPP with broad implications for disease progression from cirrhosis to HCC.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carcinogenesis / pathology
  • Carcinoma, Hepatocellular* / pathology
  • Cytosol / pathology
  • Humans
  • Liver Cirrhosis / pathology
  • Liver Neoplasms* / pathology
  • Mice
  • NADP

Substances

  • NADP